ArriVent Biopharma’s Phase 3 trial of firmonertinib fails primary endpoint
ArriVent Biopharma announced that its Phase 3 FURVENT trial in EGFR exon 20 insertion‑mutant non‑small cell lung cancer did not meet the primary progression‑free survival endpoint. The 240 mg dose showed a median PFS of 11.0 months versus 9.5 months for chemotherapy, with a hazard ratio of 0.75 that was not statistically significant. The company said it will review the full dataset to decide the next development steps. The news triggered a steep drop in AVBP shares.
Why it matters
The failure removes the immediate catalyst for firmonertinib’s regulatory approval and leaves the drug’s future uncertain, which drove a sharp sell‑off in the stock. The company’s next actions will determine whether the program can be salvaged or abandoned.
Key facts
- 1The Phase 3 FURVENT trial did not achieve its primary endpoint of progression‑free survival. investing.com
- 2The trial enrolled 398 patients globally. investing.com
- 3The 240 mg dose produced a median PFS of 11.0 months versus 9.5 months for platinum‑based chemotherapy. investing.com
- 4The hazard ratio for the 240 mg dose was 0.75 and was not statistically significant. investing.com
- 5CEO Bing Yao said the results were “not what we hoped for” and the company is evaluating the full dataset. investing.com
Open questions
- Stock decline reported as 63% in material 1 and 56.7% in material 2.
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.